GT Biopharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell GT Biopharma and other ETFs, options, and stocks.About GTBP
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells).
CEOMichael Breen
CEOMichael Breen
Employees1
Employees1
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded1965
Founded1965
Employees1
Employees1
GTBP Key Statistics
Market cap14.25M
Market cap14.25M
Price-Earnings ratio-0.14
Price-Earnings ratio-0.14
Dividend yield—
Dividend yield—
Average volume827.70K
Average volume827.70K
High today$0.4888
High today$0.4888
Low today$0.445
Low today$0.445
Open price$0.4704
Open price$0.4704
Volume863.52K
Volume863.52K
52 Week high$3.85
52 Week high$3.85
52 Week low$0.4011
52 Week low$0.4011
Stock Snapshot
The current GT Biopharma(GTBP) stock price is $0.45, with a market capitalization of 14.25M. The stock trades at a price-to-earnings (P/E) ratio of -0.14.
On 2026-03-04, GT Biopharma(GTBP) stock traded between a low of $0.45 and a high of $0.49. Shares are currently priced at $0.45, which is +2.1% above the low and -7.0% below the high.
The GT Biopharma(GTBP)'s current trading volume is 863.52K, compared to an average daily volume of 827.7K.
In the last year, GT Biopharma(GTBP) shares hit a 52-week high of $3.85 and a 52-week low of $0.40.
In the last year, GT Biopharma(GTBP) shares hit a 52-week high of $3.85 and a 52-week low of $0.40.
People also own
Based on the portfolios of people who own GTBP. This list is generated using Robinhood data, and it’s not a recommendation.